Vaccine tests in immunocompromised hosts should be encouraged to assess antibody assays associated with clinical protection as well as indirect measures such as functional and complete type-specific antibody levels

Vaccine tests in immunocompromised hosts should be encouraged to assess antibody assays associated with clinical protection as well as indirect measures such as functional and complete type-specific antibody levels. using both functional antibody assays and standard ELISA antibody titers. (ClinicalTrials.gov:NCT00307125)

Given the multifactorial nature of the human B cell malignancies, these animal models present their individual suitability to different study designs and to investigate not only the biology of human B cell malignancies but also to evaluate in vivo efficacy of new therapeutics

Given the multifactorial nature of the human B cell malignancies, these animal models present their individual suitability to different study designs and to investigate not only the biology of human B cell malignancies but also to evaluate in vivo efficacy